SCOL.ST
Scandion Oncology A/S [SCOL.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SCOL.ST Stock Summary
In the News
SCOL.ST Financial details
Company Rating
-
Market Cap
104.21M
Income
-39.2M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-2.64
Forward P/E
-
PEG
0.47
P/S
-
P/B
2.64
P/C
-
P/FCF
-2.77
Quick Ratio
4.61
Current Ratio
5.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
11.18%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-80%
SMA100
-85.71%
Inst Own
-
Inst Trans
-
ROA
-83%
ROE
-75%
ROC
-1.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.006-5.64
52W High
-99.7%
52W Low
-98.5%
RSI
53.85
Rel Volume
15.09
Avg Volume
164.9K
Volume
2.49M
Perf Week
26.05%
Perf Month
25%
Perf Quarter
-85%
Perf Half Y
-88%
-
-
-
-
Beta
1.277
-
-
Volatility
0%, 0%
Prev Close
0.67%
Price
0.015
Change
16.28%
Company Profile
- Volume Average 164.9K
- Market Capitalization 104.21M
- Employee 4
- CEO Dr. Francois Regis Martelet M.D.
- Headquarters Copenhagen,DK
- IPO Date 2018-11-08
-
Website
https://www.scandiononcology.com 
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
